Lupin gains as USFDA completed inspection without any observations

This inspection also included a review of studies done at the center’s new site at Lupin Research Park, Pune.




Shares of Lupin gained 1.5 percent intraday Wednesday after USFDA completed the inspection at its Bioresearch Centre without any observations.

United States Food and Drug Administration (USFDA) has inspected its Lupin Bioresearch Centre (LBC) without any observations. This is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility, the company said in press release.

Lupin Bioresearch Centre (LBC) conducts the in-vivo and in-vitro bioequivalence studies for Lupin in Pune.

This inspection also included a review of studies done at the center’s new site at Lupin Research Park, Pune.

Nilesh Gupta, Managing Director, Lupin expressed satisfaction about the quality management system maintained in LBC and said: “Such a high level of compliance reiterates Lupin’s commitment to high-quality standards across its world-class research centers.”

At 1046 hours, Lupin was quoting at Rs 783.10, up Rs 6.25, or 0.80 percent on the BSE.

Best Share Market News, Click Here To Get More News - Share Market tips, for 2 Days Free Trial give a missed call @9424346629 and Get Share Market Services.

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

11-year data suggests bears control D-Street in September; can bulls defy odds?

Oil prices mixed; Brent eases as trade tensions weigh